$AEMD

AETHLON MEDICAL INC

Aethlon Medical is a medical therapeutic company headquartered in San Diego, California. It develops the Hemopurifier, a clinical-stage investigational device designed to remove extracellular vesicles and enveloped viruses from biological fluids. The device uses lectin-based technology and can be used with approved dialysis machines. Aethlon Medical is conducting an oncology clinical trial in Australia involving patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy. It also studies the device for life-threatening viral infections and other applications, including organ transplantation. The FDA has granted the Hemopurifier Breakthrough Device designation for certain advanced or metastatic cancers and life-threatening viruses. The device requires clinical development and regulatory approvals before it can be marketed.

0
3
2

No SEC Form 4 filings for $AEMD in the last 30 days.

See all $AEMD insider activity →
Med

AETHLON MEDICAL INC (AEMD): Company Overview NOVEMBER 2026

AETHLON MEDICAL INC (AEMD) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Company Overview NOVEMBER 2026 1 2 Disclaimer This presentation (together with any information communicated orally in connection herewith, this "Presentation") is being pr ovi ded by North Immunology, Inc. ("North" or the "Company") on a confidential basis solely for

Aethlon Medical Reports Second Quarter Fiscal 2027 Results and Provides Corporate Update

Aethlon Medical (AEMD) reported Q2 2027 results, including $6.5M in cash, $2.7M in operating expenses, and progress in a Phase 1 oncology study. The company announced a merger with North Immunology, with shareholders to receive contingent value rights. The merger may lead to workforce reductions and wind-down of legacy activities. The company remains operational and continues to evaluate resources.

AETHLON MEDICAL INC (AEMD): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

AETHLON MEDICAL INC (AEMD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. As described in Item 5.07 below, on October 1, 2026, at the Annual Meeting of Stockholders (the “Annual Meeting”) of Aethlon

AEMD sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 5 news stories mentioning AEMD (AETHLON MEDICAL INC). Coverage has skewed bearish: 0 bullish, 3 neutral, and 2 bearish.

Recent AEMD coverage spans mergers & acquisitions, market movers and corporate actions.

What's driving AEMD

AlphAI scores every news story that mentions AEMD with an AI model for sentiment and relevance, and aggregates insider trades from AETHLON MEDICAL INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $AEMD

Score
$AEMDMedEarnings

Aethlon Medical Reports Second Quarter Fiscal 2027 Results and Provides Corporate Update

Aethlon Medical (AEMD) reported Q2 2027 results, including $6.5M in cash, $2.7M in operating expenses, and progress in a Phase 1 oncology study. The company announced a merger with North Immunology, with shareholders to receive contingent value rights. The merger may lead to workforce reductions and wind-down of legacy activities. The company remains operational and continues to evaluate resources.

$AEMDLowShareholder vote

AETHLON MEDICAL INC (AEMD): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

AETHLON MEDICAL INC (AEMD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. As described in Item 5.07 below, on October 1, 2026, at the Annual Meeting of Stockholders (the “Annual Meeting”) of Aethlon

$LSTAHighAI 9/10

Lisata and Aethlon close reverse merger deals

Lisata Therapeutics acquired Marea Therapeutics in a stock-for-stock deal with a $225M private placement, gaining access to Marea's cardioendocrine pipeline. Aethlon Medical merged with North Immunology in an all-stock deal with a $180M private placement, focusing on NOR-101 for atopic dermatitis. Both deals aim to advance pipelines and create value for shareholders.

Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead

Ultragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo

Biotech Stocks In Focus: Aethlon, Tiziana, Capricor, Firefly & Clearmind

Aethlon Medical (AEMD) surged 360% after announcing a merger with North Immunology and a $180M private placement. Tiziana Life Sciences (TLSA) rose 22% due to a clinical trial collaboration. Capricor Therapeutics (CAPR) gained 9% with upcoming Duchenne data. Firefly Neuroscience (AIFF) climbed 26% after a brain-medicine partnership. Clearmind Medicine (CMND) increased 6% following an FDA psychedelic hearing.

Related tickers